FDA Grants Breakthrough Device Designation For Advanced Prenatal Therapeutics' Targeted Apheresis Column For Preeclampsia

LAGUNA HILLS, Calif., April 17, 2019 -- (Healthcare Sales & Marketing Network) -- Advanced Prenatal Therapeutics, Inc. (APT) announced today that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device Designation for APT's Targeted Aphe... Devices, FDA Advanced Prenatal Therapeutics, Targeted Apheresis Column, Preeclampsia

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044953

Source: HSMN NewsFeed - April 17, 2019 Category: Pharmaceuticals Source Type: news

More News: Food and Drug Administration (FDA) | Grants | Marketing | Pharmaceuticals